Blood test may let some lymphoma patients skip late chemo rounds
NCT ID NCT06693830
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a new blood test (PhasED-seq) can detect leftover cancer DNA in real time during standard chemotherapy for newly diagnosed diffuse large B-cell lymphoma (DLBCL). For patients whose blood shows no cancer DNA halfway through treatment, doctors will shorten the remaining chemo from 6 to 4 cycles. The goal is to see if this approach is feasible and safe, potentially sparing patients from extra side effects. The trial enrolls 40 adults with stage II–IV DLBCL and uses no experimental drugs—only the test itself is investigational.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PhasED-seq blood test (ctDNA monitoring)
What this could lead to
If successful, this approach could allow some DLBCL patients to receive less chemotherapy, reducing side effects without compromising cancer control.
What could go wrong
This is a small, early feasibility study (40 participants) using an unapproved test. It is not designed to prove long-term outcomes, and the shortened chemo may not work as well as standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University
RECRUITINGNew York, New York, 10032, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••